? San Diego-based Adamis $ADMP saw its shares crater on the news that the FDA has rejected its application to market high-dose naloxone injection for the treatment of opioid overdose. The stock dropped about 50%, falling deep into penny stock territory. According to the biotech, the FDA had some outstanding questions on CMC that have to be resolved ahead of any approval.
? After?recently pledging ?250 million into AI adoption in the NHS, UK Prime Minister Boris Johnson vowed in his manifesto unveiled on Sunday to invest an additional